BIONET Therapeutics Corp. (TPEX:7808)

Taiwan · Delayed Price · Currency is TWD

37.00

-0.15 (-0.40%)

At close: Oct 8, 2026

Market Cap	2.59B -39.7%
Revenue (ttm)	196.63M +86.1%
Net Income	-84.09M
EPS	-1.20
Shares Out	70.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,555
Open	37.80
Previous Close	37.15
Day's Range	36.85 - 37.80
52-Week Range	28.55 - 64.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About BIONET Therapeutics

BIONET Therapeutics Corp., a biopharmaceutical company, develops regenerative medicine cell preparations for acute and severe diseases. The company develops treatment for adult respiratory distress syndrome, pulmonary fibrosis, chronic kidney disease, acute wound healing, chronic wound healing of diabetic ulcers, osteoarthritis, and dry eye syndrome. It also provides mammalian and plant sourced exosomes, and CRDMO services. The company’s pipeline includes BU-01 which is in Phase 2 trail for pulmonary fibrosis and ARDS; and is in phase 1 trials ... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2022

Employees 105

Stock Exchange Taipei Exchange

Ticker Symbol 7808

Full Company Profile

Financial Performance

In 2025, BIONET Therapeutics's revenue was 154.48 million, an increase of 89.97% compared to the previous year's 81.32 million. Losses were -97.43 million, 12.9% more than in 2024.

Financial Statements